Author: Rebecca Jones (United Kingdom)
Co-authors: Julie Hapeshi, Irene Stratton, Peter Scanlon, Sofia Theodoropoulou
Purpose
Timely assessment and treatment of patients with neovascular AMD (nAMD) is crucial to preservation of vision. Loss to follow up in these patients is a problem but this has not been systematically investigated. The problems generated by losses to follow up (LTFU) were highlighted in the 2014 HQIP/RCOphth National Ophthalmology Audit.
Setting/Venue
Undertaken at 2 district general hospitals in Gloucestershire, UK.
Methods
A retrospective review of electronic medical records of patients with nAMD first treated with anti-VEGF therapy from 1st Jan 2014 to 31st Dec 2018, was conducted in January 2021. Any patient not seen for >1 year was classed as no longer attending.
Results
Of the 1,330 patients who received an initial anti-VEGF injection, 351 were no longer attending. The annual loss to follow up rate was 5.7%, 7.4%, 7.8%, 7.5%, 8.7% and 7.1% in Year 0, 1, 2, 3, 4 and 5, respectively after starting treatment. Reasons noted for LTFU: discharged by clinician (31.3%), died (23.0%), moved to another unit outside of area (17.1%), stopped attending due to ill-health (12.8%), discharged due to failure to attend (5.7%) and patient choice to no longer attend (4.0%). Interestingly, the median VA for LTFU was 0.78.
Conlusions
Understanding the factors influencing LTFU rate is crucial to addressing gaps in a hospital AMD service. When analyzing visual outcomes in an AMD service, those who are LTFU are important to characterize, as the outcomes for this group may be avoidably poor.
Financial Disclosure
Nil
Comments
-